Pliant Therapeutics Inc. reported a net loss of $26.3 million for the third quarter of 2025, compared to a net loss of $57.8 million in the same period last year. Research and development expenses were $17.9 million, down from $47.8 million, primarily due to the discontinuation of the BEACON-IPF program. General and administrative expenses decreased to $10.3 million from $14.3 million, mainly due to lower personnel-related costs following a strategic workforce restructuring. As of September 30, 2025, the company had $243.3 million in cash, cash equivalents, and short-term investments. Key business developments include the completion of enrollment in the Phase 1 trial of PLN-101095 in solid tumors and the winding down of BEACON-IPF activities, with close out expected in the fourth quarter of 2025.